The Claim
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) by 11% in type 2 diabetes patients without established atherosclerotic cardiovascular disease (ASCVD), based on pooled data from seven randomized controlled trials involving 13,409 patients, with an absolute risk reduction of 0.92% over three years and a number needed to treat of 109 to prevent one MACE event.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with type 2 diabetes but no prior heart disease, GLP-1 receptor agonists lower the chance of serious heart problems such as heart attack, stroke, or death by 11% over three years compared to no such treatment.
See the scientific wording
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) by 11% in type 2 diabetes patients without established atherosclerotic cardiovascular disease (ASCVD), based on pooled data from seven randomized controlled trials involving 13,409 patients, with an absolute risk reduction of 0.92% over three years and a number needed to treat of 109 to prevent one MACE event.
GLP-1 receptor agonists activate receptors in blood vessel walls and the pancreas, which lowers blood sugar, reduces inflammation in artery walls, and decreases the buildup of fatty plaques, making heart attacks and strokes less likely.
What the research says
1 studyIn people with type 2 diabetes but no prior heart disease, taking GLP-1 drugs slightly lowers the chance of serious heart problems — about 1 in 109 people will avoid a heart event over three years. The study confirms this exact number.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.